녹내장치료에 있어서 Tafluprost와 Latanoprost의 경제성평가
Pharmacoeconomic Analysis of Tafluprost compared with Latanoprost on the Treatment of Primary open Angle Glaucoma or Ocular Hypertension in Korea
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
The main objective of this study is to evaluate the cost-effectiveness of tafluprost compared with latanoprost in primry open Angle Glaucoma (POAG) or ocular hypertension OH patients in Korea. A decision analytic model was developed from a societal perspective to estimate clinical outcome, drug cost and glaucoma related cost. The model assumes branch like following: successful treatment, switching to other drug, adding other drug, laser or surgery. Treatment success rate is defined as the percentage of patients with elevated IOP achieving <20% reduction, and discontinuation rate is the percentage of patients who were withdrawn due to severe adverse events. A model that is comprised of 1 month cycle length has 1 year. Treatment success rate and discontinuation rate were obtained from published literatures searched in database. Resource utilizations and costs were calculated with national health insurance data and clinical expert opinions. Sensitivity analyses were performed on crucial parameters. Tafluprost is less costly than latanoprost,$609.0 vs $651.2 expected cost. Thus tafluprost was shown to be dominant compared with latanoprost. The results of sensitivity analysis revealed stable across most of the included parameters. According to this study, tafluprost shows more clinical outcome for 1 year than latanoprost. In addition, first-line treatment of tafluprost is a more cost-minimizing strategy associated with POAG or OH compared with latanoprost.
Abstract
The main objective of this study is to evaluate the cost-effectiveness of tafluprost compared with latanoprost in primry open Angle Glaucoma (POAG) or ocular hypertension OH patients in Korea. A decision analytic model was developed from a societal perspective to estimate clinical outcome, drug cost and glaucoma related cost. The model assumes branch like following: successful treatment, switching to other drug, adding other drug, laser or surgery. Treatment success rate is defined as the percentage of patients with elevated IOP achieving <20% reduction, and discontinuation rate is the percentage of patients who were withdrawn due to severe adverse events. A model that is comprised of 1 month cycle length has 1 year. Treatment success rate and discontinuation rate were obtained from published literatures searched in database. Resource utilizations and costs were calculated with national health insurance data and clinical expert opinions. Sensitivity analyses were performed on crucial parameters. Tafluprost is less costly than latanoprost,$609.0 vs $651.2 expected cost. Thus tafluprost was shown to be dominant compared with latanoprost. The results of sensitivity analysis revealed stable across most of the included parameters. According to this study, tafluprost shows more clinical outcome for 1 year than latanoprost. In addition, first-line treatment of tafluprost is a more cost-minimizing strategy associated with POAG or OH compared with latanoprost.
참고문헌 (21)
- "정상 안압 녹내장 자료"[URL]
- Ikeda Y, "Effects of switching from topical beta-blockers to latanoprost on intraocular pressure in patients with normal-tension glaucoma", J Ocul Pharmacol Ther, 24(2), pp.230~234 (2008)
- He M, "Prevalence and clinical characteristics of glaucoma in adult Chinese: a populationbased study in Liwan district, Guangzhou", Invest Ophthalmol Vis Sci, 47, pp.2782~ (2006)
- Netland PA, "Robertson SM, Davis AA; Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension", Am J Ophthalmol, 132(4), pp.472~484 (2001)
- Boyle JE, "A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide", Ophthalmology, 106(12 Suppl), pp.10~16 (1999)
- Hommer A, "A European perspective on costs and cost effectiveness of ophthalmic combinations in the treatment of open-angle glaucoma", Eur J Ophthalmol, 18(5), pp.778~786 (2008)
- Hommer A, "A costeffectiveness analysis of fixed-combination therapies in patients with open-angle glaucoma: a European perspective", Curr Med Res Opin, 24(4), pp.1057~1063 (2008)
- Lachaine J, "Prostaglandin analogues for ophthalmic use: a cost-effectiveness analysis", Can J Ophthalmol, 43(1), pp.33~41 (2008)
- Payet S, "Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France", Clin Drug Investig, 28(3), pp.183~198 (2008)
- Goldberg LD, "Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications", Pharmacoeconomics, 24(3), pp.251~264 (2006)
- Holmstrom S, "The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries", Curr Med Res Opin, 22(5), pp.897~905 (2006)
- Bernard LM, "Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France", Eur J Ophthalmol, 13(Suppl 4), pp.S30~43 (2003)
- M. Cristina Leske, "Bo Bengtsson and Eugene Komaroff, Factors for progression and glaucoma treatment: The Early Manifest Glaucoma Trial", Current Opinion in Ophthalmology, 15, pp.102~106 (2004)
- Burr JM, "The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation", Health Technol Assess, 11(41), pp.1~190 (2007)
- Kuwayama Y, "Phase III confirmatory study of 0.0015% DE-085 (Tafluprost) ophthalmic solution as compared to 0.005% Latanoprost ophthalmic solution in patients with open-angle glaucoma or ocular hypertension", Atarashii Ganka, 25, pp.1595~1602 (2008)
- Ikeda Y, "Latanoprost nonresponders with open-angle glaucoma in the Japanese population", Jpn J Ophthalmol, 50(2), pp.153~157 (2006)
- 홍철, "외래환자를 대상으로한녹내장역학조사다기관연구", 한국녹내장연구회 (2006)
- Rylander NR, "Cost analysis of glaucoma medications", Am J Ophthalmol, 145(1), pp.106~113 (2008)
- Lesk MR, "Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension", Ann Pharmacother, 42(4), pp.498~504 (2008)
- Cantor LB, "Alphagan", Betaxolol Clinical Success Study Group. Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25% suspension in patients with elevated intraocular pressure, 2001, pp.23(7), 1032~1039
- DuBiner HB, "Brimonidine vs. Latanoprost Study Group. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial", Clin Ther, 23(12), pp.1969~1983 (2001)